Description:

AIDS-Related Non-Hodgkin's Lymphoma Baseline Lymphoma Disease Activity and Assessment (LAA) Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma NCT00310128 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=11409201-BB50-09A2-E044-0003BA3F9857

Link:

https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=11409201-BB50-09A2-E044-0003BA3F9857

Keywords:
Versions (2) ▾
  1. 8/26/12
  2. 2/3/15
Uploaded on:

February 3, 2015

DOI:
No DOI assigned. To request one pleaselog in.
License:
Creative Commons BY-NC 3.0 Legacy
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Baseline Lymphoma Disease Activity and Assessment

No Instruction available.

  1. StudyEvent: Baseline Lymphoma Disease Activity and Assessment (LAA)
    1. No Instruction available.
Lymphoma disease activity
Modified Ann Arbor Stage
Recurring, drenching night sweats during the previous month
Unexplained, persistent fever >38 degrees C (or >100 degrees F) in the previous month
Unexplained weight loss above 10% of body weight in the previous 6 months
Hematopoietic Diagnosis
If diffuse large B-cell lymphoma, specify morphologic type
If Burkitt lymphoma/leukemia, specify morphologic type
Method of Evaluation
Is the participant >60 years of age
Does the participant have Stage III or IV disease
Is the serum LDH elevated
Is the ECOG Performance Status 2, 3, or 4
Does the participant have two or more extranodal disease sites
IPI Risk Category